The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Trastuzumab deruxtecan in patients in the USA and Europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a trastuzumab-containing regimen (DESTINY-Gastric02): primary and updated analyses from a single-arm, phase 2 study
Open accessAbstract
Background Approximately 15‒20% of advanced gastric and gastroesophageal junction (GEJ) cancers overexpress HER2. In DESTINY-Gastric01, the HER2-targeted antibody-drug conjugate trastuzumab deruxtecan (T-DXd) improved response and overall survival (OS) versus chemotherapy in patients from Japan and Korea with locally advanced and/or metastatic HER2-positive gastric or GEJ cancer whose disease progressed after two lines of therapy including trastuzumab. Here, we report data from the single-arm, phase 2 DESTINY-Gastric02 trial, which examines T-DXd in Western patients. Methods DESTINY-Gastric02 is a multicentre, single-arm study in adult patients from the United States and Europe. Eligible patients were aged ≥18 years, had an Eastern Cooperative Oncology Group performance status of 0 or 1, had pathologically documented unresectable or metastatic gastric/GEJ cancer, had progressive disease on or after first-line therapy with a trastuzumab regimen, and had centrally confirmed HER2-positive disease on a postprogression biopsy. Patients received 6·4 mg/kg of T-DXd intravenously every 3 weeks until disease progression, withdrawal by patient, physician decision, or death. The primary endpoint was confirmed objective response rate by independent central review (ICR) which was assessed in the full analysis set. Safety was assessed in the safety analysis set. This ongoing trial is registered with ClinicalTrials.gov, NCT04014075. Findings Between November 26, 2019, and November 8, 2021, 79 patients were treated with T-DXd (57 male, 22 female), with a median follow-up of 10·2 months (IQR 5·6‒12·9 months). A confirmed objective response was reported in 33 patients (41·8% [95% CI 30·8‒53·4]), as assessed by ICR. The most common grade ≥3 treatment-emergent adverse events (TEAEs) occurring in ≥5% of patients were anaemia (n=11; 13·9%), nausea (n=6; 7·6%), neutrophil count decrease (n=6; 7·6%), and white blood cell decrease (n=5; 6·3%). Drug-related serious TEAEs occurred in 10 patients (12·7%). Drug-related TEAEs associated with the outcome of death occurred in 2 patients (2·5%) and were due to interstitial lung disease/pneumonitis. Eight patients (10·1%) had adjudicated drug-related interstitial lung disease/pneumonitis (two grade 1 [2·5%], four grade 2 [5·1%], and two grade 5 [2·5%]). Interpretation These clinically meaningful results, demonstrated by the robust ORR, prolonged PFS and OS, and tolerable safety profile, support the use of T-DXd as second-line therapy in patients with HER2-positive advanced gastric/GEJ cancer. Funding Daiichi Sankyo
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bang, Y.-J., Van Cutsem, E., Feyereislova, A., Chung, H. C., Shen, L., Sawaki, A., Lordick, F., Ohtsu, A., Omuro, Y., Satoh, T., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61121-x · Cited by 7,302
Self-citationWilke, H., Muro, K., Van Cutsem, E., Oh, S.-C., Bodoky, G., Shimada, Y., Hironaka, S., Sugimoto, N., Lipatov, O., Kim, T.-Y., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70420-6 · Cited by 2,438
Self-citationTrastuzumab deruxtecan in previously treated HER2-positive gastric cancer
Shitara, K., Bang, Y.-J., Iwasa, S., Sugimoto, N., Ryu, M.-H., Sakai, D., Chung, H.-C., Kawakami, H., Yabusaki, H., Lee, J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2004413 · Cited by 1,333
Self-citationOgitani, Y., Aida, T., Hagihara, K., Yamaguchi, J., Ishii, C., Harada, N., Soma, M., Okamoto, H., Oitate, M., Arakawa, S., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2822 · Cited by 1,177
Satoh, T., Xu, R.-H., Chung, H. C., Sun, G.-P., Doi, T., Xu, J.-M., Tsuji, A., Omuro, Y., Li, J., Wang, J.-W., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.6136 · Cited by 624
HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer
Van Cutsem, E., Bang, Y.-J., Feng-yi, F., Xu, J. M., Lee, K.-W., Jiao, S.-C., Chong, J. L., López-Sanchez, R. I., Price, T., Gladkov, O., et al. (2015) · Gastric Cancer · doi:10.1007/s10120-014-0402-y · Cited by 608
Self-citationThuss-Patience, P. C., Shah, M. A., Ohtsu, A., Van Cutsem, E., Ajani, J. A., Castro, H., Mansoor, W., Chung, H. C., Bodoky, G., Shitara, K., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30111-0 · Cited by 547
Self-citationDoi, T., Shitara, K., Naito, Y., Shimomura, A., Fujiwara, Y., Yonemori, K., Shimizu, C., Shimoi, T., Kuboki, Y., Matsubara, N., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30604-6 · Cited by 505
Nakada, T., Sugihara, K., Jikoh, T., Abe, Y., & Agatsuma, T. (2019) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.c18-00744 · Cited by 442
Changing Trends in Stomach Cancer Throughout the World
Balakrishnan, M., George, R., Sharma, A., & Graham, D. Y. (2017) · Current Gastroenterology Reports · doi:10.1007/s11894-017-0575-8 · Cited by 384
Cited by
Goto, K., Goto, Y., Kubo, T., Ninomiya, K., Kim, S.-W., Planchard, D., Ahn, M.-J., Smit, E. F., de Langen, A. J., Pérol, M., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.23.01361 · Cited by 328
The Journey of Antibody–Drug Conjugates: Lessons Learned from 40 Years of Development
Colombo, R., Tarantino, P., Rich, J. R., LoRusso, P. M., & de Vries, E. G. E. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0708 · Cited by 254
A B7H3-targeting antibody–drug conjugate in advanced solid tumors: a phase 1/1b trial
Ma, Y., Yang, Y., Huang, Y., Fang, W., Xue, J., Meng, X., Fan, Y., Fu, S., Wu, L., Zheng, Y., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-03600-2 · Cited by 122
Metadata
- Authors
- Van Cutsem, E., di Bartolomeo, M., Smyth, E., Chau, I., Park, H., Siena, S., Lonardi, S., Wainberg, Z. A., Ajani, J., Chao, J., Janjigian, Y., Qin, A., Singh, J., Barlaskar, F., Kawaguchi, Y., & Ku, G.
- Venue
- The Lancet Oncology
- Publisher
- Elsevier BV
- Published
- 2023-07
- Volume
- 24
- Issue
- 7
- Pages
- 744-756
- ISSN
- 1470-2045 (ISSN-L)
- OpenAlex
- W4380738795
- Cited by
- 265
- References
- 21
- FWCI
- 41.62
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Trastuzumab deruxtecan in patients in the USA and Europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a trastuzumab-containing regimen (DESTINY-Gastric02): primary and updated analyses from a single-arm, phase 2 study. https://app.cochat.ai/papers/10.1016/s1470-2045(23)00215-2
- The paper
- Van Cutsem, E., di Bartolomeo, M., Smyth, E., Chau, I., Park, H., Siena, S., Lonardi, S., Wainberg, Z. A., Ajani, J., Chao, J., Janjigian, Y., Qin, A., Singh, J., Barlaskar, F., Kawaguchi, Y., & Ku, G. (2023). Trastuzumab deruxtecan in patients in the USA and Europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a trastuzumab-containing regimen (DESTINY-Gastric02): primary and updated analyses from a single-arm, phase 2 study. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(23)00215-2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.